GlaxoSmithKline said on Monday it had agreed to buy U.S. cancer drug specialist Tesaro for $5.1 billion, marking a major biotech investment by the British drugmaker as its seeks to rebuild its pharmaceuticals portfolio.
Source:: Reuters – Business News
